Precision therapy through affinity-based antibody conjugation
Latest News
February 4, 2025
Per Norlén joins Strike Pharma as new CEO
September 10, 2024
Strike Pharma presents updates at CICON24
July 4, 2024
Strike Pharma granted patent to protect core technology
July 4, 2024
Strike Pharma receives funding from BIO-X Accelerate program
September 24, 2023
Strike Pharma presents further developments at CICON23
May 16, 2023
Strike Pharma and FyoniBio conclude successful cell line development of Strike’s bi-specific antibody and clinical lead candidate
April 18, 2023
Strike Pharma presents latest developments at AACR 2023
December 5, 2022
Funds awarded to study ADAC™ technology in depth
November 3, 2022
Strike Pharma continues expansion of management team
October 20, 2022
Strike Pharma and FyoniBio sign Master Service Agreement
August 30, 2022
Strike Pharma’s Chief Scientific Officer receives BiotechBuilders Award 2022
June 20, 2022
Strike Pharma strengthens Board of Directors
We use cookies to give you the best experience on our website. Do you accept the use of cookies?
